Stockreport

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease [Yahoo! Finance]

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor ® (rexlemestrocel-L) an Orphan-Drug [Read more]